CDER Director Patrizia Cavazzoni and CBER Director Peter Marks provided an update on the rare disease innovation hub in a new FDA Voices blog post.

Brian Feth and Jonathan Grinstein go behind the headlines to discuss the impact of a Republican administration on Federal ...

Pharmaceutical Technology® caught up with Brittany Hayes, PhD, Highly Potent & Oncology Platform Director at CordenPharma, ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Traditional formulations commonly struggle to achieve content uniformity with morphologically challenging active pharmaceutical ingredients (APIs), requiring the use of complicated processes such as ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification ...

Biopharma companies often lack the capacity and infrastructure to handle large buffer volumes needed for mAb production. Avantor offers four key strategies to improve operational efficiencies and ...